Zobrazeno 1 - 10
of 954
pro vyhledávání: '"Antimuscarinics"'
Publikováno v:
Continence, Vol 12, Iss , Pp 101707- (2024)
Antimuscarinics have long been the cornerstone of treatment for overactive bladder (OAB), with their use spanning decades. This paper reviews the pharmacological properties, historical use, clinical efficacy, and challenges associated with antimuscar
Externí odkaz:
https://doaj.org/article/50c7b233da0448b5a9a142ca5ee26349
Autor:
Luisa Gracio Ferreira Sartori, Bruno Monteiro Nunes, Daniela Farah, Leticia Maria de Oliveira, Claudia Cristina Takano Novoa, Marair Gracio Ferreira Sartori, Marcelo Cunio Machado Fonseca
Publikováno v:
Revista Brasileira de Ginecologia e Obstetrícia, Vol 45, Iss 6, Pp 337-346 (2023)
Abstract Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September
Externí odkaz:
https://doaj.org/article/edf3c2434cdd4891a1370bbdd55fc6c1
Publikováno v:
Continence, Vol 9, Iss , Pp 101064- (2024)
Externí odkaz:
https://doaj.org/article/14d437ad33264e52a7398a73a064089c
Publikováno v:
International Journal of Women's Health, Vol Volume 15, Pp 799-811 (2023)
Dudley Robinson, Miriam O’Kane, Linda Cardozo Department of Urogynaecology, King’s College Hospital, London, UKCorrespondence: Dudley Robinson, Department of Urogynaecology, King’s College Hospital, Suite 8, Level 3, Golden Jubilee Wing, London
Externí odkaz:
https://doaj.org/article/65ae77a5d46841d9a905a0d5a4230fac
Publikováno v:
Continence, Vol 8, Iss , Pp 101047- (2023)
Aims:: Bladder contractility is altered by high doses of anticholinergics. It is unknown if anticholinergics at doses used for treating overactive bladder alter bladder contractility. This is a randomised, double-blind, placebo controlled cross-over
Externí odkaz:
https://doaj.org/article/0f990bf09f2a44b4b27fcaaa026ab86b
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Objective: We conducted a meta-analysis to assess the efficacy and safety of mirabegron (50 mg/day) and antimuscarinics in treating ureteral stent-related symptoms (SRSs).Methods: All randomized controlled trials (RCTs) were identified by searching P
Externí odkaz:
https://doaj.org/article/98229e8205f943b68bcc38f3648c1c5d
Autor:
Yuh-Chen Kuo, Hann-Chorng Kuo
Publikováno v:
Tzu-Chi Medical Journal, Vol 35, Iss 1, Pp 62-68 (2023)
Objectives: To compare the therapeutic efficacy, adverse events (AEs), and patient preference in elderly patients with overactive bladder (OAB) receiving different combinations of mirabegron and solifenacin. Materials and Methods: Elderly OAB patient
Externí odkaz:
https://doaj.org/article/6d87582a85224d838cd4a3f03d552132
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 10, Pp 2101-2108 (2022)
Purpose: This cohort study evaluates therapeutic efficacy and adverse events (AEs) of various overactive bladder (OAB) medications for patients with central nervous system (CNS) disorders. Methods: Patients with OAB and CNS disorders were prospective
Externí odkaz:
https://doaj.org/article/70ac58de1ddd43a8b7c7fccd9bc90f2b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hann-Chorng Kuo
Publikováno v:
Tzu-Chi Medical Journal, Vol 34, Iss 1, Pp 23-28 (2022)
Medical treatment of overactive bladder (OAB) includes antimuscarinic agents, beta-3 adrenoceptor agonist (mirabegron), or combination with both drugs. Recently, a meta-analysis reported the integrated clinical trial data from 10 phase 2–4, double-
Externí odkaz:
https://doaj.org/article/99c29668ad1741cca82006d36cc34e34